|
Shanghai Newsummit Biopharma Group is a CRO (Collaboration Research Organization) company with business focus on back-end R&D service and investment for new drug development. With new drug PCRD (Platform Chain of R&D) as the carrier, it is engaged in providing services during the whole process of biopharmaceutical industry.
Deploying PCRD Oceania Strategy within the framework of in-depth cooperation with governmental science parks, Newsummit Group cooperates with major national science parks, integrates regional resources, builds new drug PCRD (Platform Chain of R&D) and provides one stop professional solutions to new drug industrialization. Newsummit has built and is now operating multiple new drug R&D service platforms in several national biopharmaceutical science parks. In following three years, 1.66 billion RMB will be allocated and invested to build regional PCRDs, and therefore a high efficiently integrated, resource-sharing, regionally interactive operating mechanism of PCRD network will be in place to form an innovative new drug development system.
The unique GRDP (Good Practice in the Research and Development of New Drug) has been applied in the new drug development system to make the development process modularized, standardized and pipelining, which in return reduces research costs, shortens research period cycle, industrializes new drug projects for scientists, provides industrialization values for entrepreneurs, lowers the investment risks for investors and increases scientific service capability for science parks.
Operation Model: market oriented operation with corporate as main body and government as driven force.
Business focus: back-end R&D service and investment for new drug development
Operation model: pipelining, modularized and high flux new drug R&D service in large scale on the carrier of new drug PCRD (Platform Chain of R&D)
Business model: Revenue from CRO service--- medium and long term investment return ---capital market connection
Service model: providing one stop total solution and one stop integrated services
Business scope:
« Domestic and international registration services: IND/NDA registration service for innovative drugs bearing oversea research results on various phases
« Jointly build clinical research enters, non-clinical research centers and industrialization base complying with international standard
« CRO/CMO service: 1, New drug quality standard research; 2, Pilot-Industrialization research service 3, non-clinical and clinical research services; 4, Industrialization Research and GMP Certification based on the GRDP/GMP standard; 5, Clinical studies for drug
|
